Stay updated with breaking news from Launch Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- At three months post-launch, the high expectations for Biogen/Eisai's Aduhelm in Alzheimer's disease have not quite materialized....
/PRNewswire/ -- Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and...
/PRNewswire/ -- The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As...
Share this article Share this article EXTON, Pa., Feb. 17, 2021 /PRNewswire/ -- Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis' Cosentyx and Eli Lilly's Taltz, have since experienced rapid uptake. According to feedback from 97 US rheumatologists in the latest report included in Spherix's RealTime Dynamix ™ service, the official entrance of the IL-17 inhibitors is causing a shift in the market where UCB's Cimzia previously held the position as the only biologic with commercial avail...
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis News provided by Share this article Share this article EXTON, Pa., Jan. 29, 2021 /PRNewswire/ -- Spherix Global Insights, a leading...